IMMIX BIOPHARMA, INC.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — |
| Operating Expenses | |||||||
| Research & Development | — | $16.3M | $11.3M | $8.7M | $4.2M | $126.5K | $248.1K |
| SG&A Expense | — | $13.7M | $11.4M | $7.4M | $4.0M | $1.2M | $205.7K |
| Operating Income | — | $-30.0M | $-22.7M | $-16.1M | $-8.2M | $-1.4M | $-453.9K |
| Operating Margin | — | — | — | — | — | — | — |
| Interest Expense | — | — | — | — | $497 | $179.9K | $102.0K |
| Pretax Income | — | $-29.4M | $-21.7M | $-15.6M | $-8.2M | $-24.4M | $-1.1M |
| Income Tax Expense | — | $37.7K | $41.0K | $26.4K | $10.3K | $6.0K | $17.5K |
| Net Income | — | $-29.4M | $-21.6M | $-15.4M | $-8.2M | $-24.4M | $-1.1M |
| Net Margin | — | — | — | — | — | — | — |
| EPS (Basic) | — | $-0.89 | $-0.76 | $-0.89 | $-0.59 | $-1.66 | $-0.09 |
| EPS (Diluted) | — | $-0.89 | $-0.76 | $-0.89 | $-0.59 | $-1.66 | $-0.09 |
| Shares Outstanding (Basic) | 53.0M | 33.0M | 28.3M | 17.3M | 13.9M | 14.7M | 13.5M |
| Shares Outstanding (Diluted) | 53.0M | 33.0M | 28.3M | 17.3M | 13.9M | 14.7M | 13.5M |
| Dividends Per Share | — | — | — | — | — | — | — |